Contrasting Globus Medical (NYSE:GMED) and Bluejay Diagnostics (NASDAQ:BJDX)

Globus Medical (NYSE:GMED) and Bluejay Diagnostics (NASDAQ:BJDX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, dividends, analyst recommendations and risk.

Earnings and Valuation

This table compares Globus Medical and Bluejay Diagnostics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.52 billion	4.52	$102.98 million	$3.10	27.44
Bluejay Diagnostics	$250,000.00	6.81	-$7.72 million	($118.16)	-0.01

Globus Medical has higher revenue and earnings than Bluejay Diagnostics. Bluejay Diagnostics is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Globus Medical has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500. Comparatively, Bluejay Diagnostics has a beta of 0.61, indicating that its stock price is 39% less volatile than the S&P 500.

Institutional and Insider Ownership

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 18.5% of Globus Medical shares are held by company insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Globus Medical and Bluejay Diagnostics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Globus Medical	15.30%	11.52%	9.76%
Bluejay Diagnostics	N/A	-432.21%	-345.69%

Analyst Recommendations

This is a breakdown of current ratings and target prices for Globus Medical and Bluejay Diagnostics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0	6	8	0	2.57
Bluejay Diagnostics	1	0	0	0	1.00

Globus Medical presently has a consensus target price of $93.11, indicating a potential upside of 9.45%. Given Globus Medical’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Globus Medical is more favorable than Bluejay Diagnostics.

Summary

Globus Medical beats Bluejay Diagnostics on 13 of the 14 factors compared between the two stocks.

About Globus Medical

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. It also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, the company distributes human cell, tissue, and cellular and tissue-based products. It sells its products through direct or distributor sales representatives, as well as hip and knee products through independent sales agents. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.

About Bluejay Diagnostics

Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.